Introduction: In early 2011, the FDA gave approval to a new preparation of gabapentin, licensed for the treatment of post-herpetic neuralgia (PHN). Gabapentin is commonly used worldwide for multiple indications, which include neuropathic pain. The new drug combines generic gabapentin with a polymeric delivery system allowing for extended release and is licensed to be given only as a once-daily dosing regimen.
Areas covered: The article aims to review the available evidence relating to the pharmacokinetics, tolerability and efficacy of extended-release gabapentin (GpER). It addresses the current state of the drug's progress through regulation and the intention of its manufacturer for the market.
Expert opinion: Although GpER has been approved by the FDA for once-daily use in PHN, there is a relative paucity of data for both its efficacy and the optimum dosing schedule (once or twice a day). There are no data directly comparing GpER with the immediate-release preparation or other first-line treatments for PHN. Therefore, the true status of GpER as a treatment option needs to be enhanced with additional experimental evidence for its efficacy and favourable side-effect profile.